We provide market intelligence focused on earnings data and stock price behavior.
As of 2026-04-20, Drugs Made In America Acquisition Corp. Rights (DMAAR) trades at a current price of $0.08, marking a 6.98% decline on the day. As a rights instrument tied to a healthcare-focused special purpose acquisition corporation (SPAC) focused on domestic pharmaceutical manufacturing assets, DMAAR has garnered attention from investors tracking the domestic biomanufacturing and SPAC spaces. This analysis covers recent market context for the name, key technical levels to monitor, and poten
Is AmericanDrug (DMAAR) stock exposed to downside risk (Selloff Intensifies) 2026-04-20 - SuperTrend
DMAAR - Stock Analysis
4740 Comments
786 Likes
1
Rainne
Power User
2 hours ago
{协议答案}
👍 123
Reply
2
Glin
Insight Reader
5 hours ago
{协议答案}
👍 124
Reply
3
Jahcier
Engaged Reader
1 day ago
{协议答案}
👍 147
Reply
4
Sebastino
Community Member
1 day ago
{协议答案}
👍 35
Reply
5
Clariza
Insight Reader
2 days ago
{协议答案}
👍 160
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.